



# DID YOU KNOW ?

Accidental drug ingestion in children five years old and below, causes **50,000 VISITS** to the ER per year.<sup>1</sup>

-CDC

Accidental drug poisonings happen in **JUST ONE MINUTE** when parents turn their back on their child.<sup>2</sup>



## CHILD-RESISTANT PACKAGING


According to the PPPA in the US, 'child-resistant' or 'special packaging' is a package that is significantly difficult for children under 5 to open but relatively easy for an adult to open.<sup>3-5</sup>

CHILD-RESISTANT PACKAGING has been shown to prevent accidental drug poisonings.<sup>6</sup>

## LAMICTAL CHILD-RESISTANT BLISTER<sup>b</sup>

3 simple steps to open Lamictal Child-resistant blister<sup>7</sup>

1



### SEPARATE ONE TABLET

Tear along the cutting lines to separate one 'pocket' from the blister.

2



### PEEL BACK THE OUTER LAYER

Starting at the corner, lift and peel over the pocket.

3



### PUSH OUT THE TABLET

Gently push the tablet through the foil layer.

*These images are for illustration purposes only and may not be an exact representation of the product.*



Child-resistant packaging is the last line of defence in a series of protective measures. Parents or guardians are advised to keep medicinal products out of sight and out of reach from young children to ensure their safety.<sup>5</sup>

<sup>a</sup>A package is deemed to be child-resistant if at least 85% of children (42-51 months) are unable to access more than eight unit doses within the first five minutes and at least 80% of children are unable to access more than eight unit doses within ten minutes, while 90% of adults are able to access at least one unit dose in one minute.<sup>5</sup>

<sup>b</sup>Lamictal 25 mg, 50 mg, 100 mg and 200 mg chewable/dispersible tablets come in child-resistant packaging.<sup>7</sup>

**References:** **1.** CDC. PROTECT Initiative: Advancing Children's Medication Safety. Last updated April 2020; **2.** Safe Medicine Storage: Recent Trends and Insights for Families and Health Educators. March 2018; **3.** United States Consumer Product Safety Commission. Business Guidance FAQ. Child Resistant and Senior Friendly Packaging (PPPA). <https://www.cpsc.gov/Business--Manufacturing/Business-Education/FAQ?p=3061&tid%5b3069%5d=3069>. Accessed Jan 2023. **4.** Child Resistant Packaging. Consumer Healthcare Products Association <https://www.chpa.org/public-policy-regulatory/regulation/regulation-otc-medicines/child-resistant-packaging>. Accessed Mar 2023. **5.** ISO 14375:2018 Child-resistant non-reclosable packaging for pharmaceutical products — Requirements and testing. <https://www.iso.org/obp/ui/#iso:std:iso:14375:ed-1:vi:en>. Accessed on Mar 2023. **6.** White et al. *American journal of lifestyle medicine*. 2018 Mar;*12*(2):117-9. **7.** Lamotrigine Global Datasheet, v50, January 2021

#### Abbreviations:

CDC: Centers for Disease Control and Prevention; ER: Emergency Room;

PPPA: Poison Prevention Packaging Act; US: United States

**This leaflet is for educational purposes only. Consult your healthcare provider to seek further medical advice.**

Kindly reach out to us at [HELPLINE NUMBER] for any concerns.

Adverse events should be reported. For the [INSERT COUNTRY], reporting forms and information can be found at [INSERT LINK OR OTHER CONTACT INFORMATION].

If you have any comments or questions; please contact us on (LOC Entity Name, Address and Registered contact number).

Materials supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.

Copyright © GlaxoSmithKline 2023. All rights reserved.

GlaxoSmithKline Limited. Registered in [COUNTRY, CODE]

Trademarks are owned by or licensed to the GlaxoSmithKline group of companies.

NP-GBL-LMT-LBND-230002

Date of preparation: March 2023



Electronic Certificate

Version: 1 . 0

Document Number: NP-GBL-LMT-LBND-230002

Document Name: Lamictal Blister Leave Behind

Country: Global

Product: LAMICTAL

Type: Non-promotional content

Role	Signature
Sanman Ghorpade - Medical (sanman.a.ghorpade@gsk.com)	It is approved that this material has been examined and is believed to be in accordance with the relevant Code of Practice and any other relevant regulations, policies and SOPs. Date: 28-Mar-2023 12:06:05 GMT+0000
Sai Janane Barnee - Other (role not listed) (sai-janane.x.barnee@gsk.com)	It is approved that this material has been examined and is believed to be in accordance with the relevant Code of Practice and any other relevant regulations, policies and SOPs. Date: 29-Mar-2023 10:28:10 GMT+0000
Rio Carla Pineda - IMR (rio-carla.f.pineda@gsk.com)	It is approved that this material has been examined and is believed to be in accordance with the relevant Code of Practice and any other relevant regulations, policies and SOPs. Date: 29-Mar-2023 11:57:56 GMT+0000